Key result
Right heart catheterization confirms PAH, directing therapy across three approved drug classes.
Provides a comprehensive clinical review of the diagnostic workup—emphasizing right heart catheterization with vasodilator testing—and evidence-based pharmacological management of WHO Group 1 pulmonary arterial hypertension across three approved drug classes.
Answers are grounded in this paper and cite their sources.
Reaffirms right heart catheterization and approved drug classes for pulmonary arterial hypertension; leaves open evaluation of emerging agents in prospective trials.
Pulmonary arterial hypertension is a rare disease, which requires a high index of suspicion to diagnose when patients initially present. Initial symptoms can be nonspecific and include complaints such as fatigue and mild dyspnea. Once the disease is suspected, echocardiography is used to estimate the pulmonary arterial (PA) pressure and to exclude secondary causes of elevated PA pressures such as left heart disease. Right heart catheterization with vasodilator challenge is critical to the proper assessment of pulmonary hemodynamics and to determine whether patients are likely to benefit from vasodilator therapy. Pathologically, the disease is characterized by deleterious remodeling of the distal pulmonary arterial and arteriolar circulation, which results in increased pulmonary vascular resistance. In the last fifteen years, medications from three different classes have been approved for the treatment of pulmonary arterial hypertension. These include the prostanoids, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors.
No takes yet. Share an insight, caveat, or question.
Houtchens et al. (2011) conducted a review in Pulmonary arterial hypertension (WHO Group 1). Pulmonary arterial hypertension diagnostic evaluation (echocardiography and right heart catheterization with vasodilator challenge) and targeted pharmacotherapy (prostanoids, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors) was evaluated. Definitive diagnosis of pulmonary arterial hypertension requires right heart catheterization with vasodilator testing, and approved treatment spans prostanoids, endothelin receptor antagonists, and PDE-5 inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: